- Kindeva is marking 70 years since the invention of the pressurized metered dose inhaler (pMDI), with its inventors inducted into the National Inventors Hall of Fame.
- The company continues to invest in inhalation innovation, including a new centre of excellence in the UK and development of next-generation propellants.
Kindeva has marked the 70th anniversary of the pressurized metered dose inhaler (pMDI), a drug delivery technology introduced in 1956, while announcing that its original inventors will be inducted into the National Inventors Hall of Fame. The CDMO and drug delivery company said former colleagues George Maison, Irving Porush, and Charles Thiel will be formally recognized for their contribution to respiratory care.
The pMDI was developed as a portable alternative to squeeze-bulb nebulizers and became widely adopted for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to the company, its introduction contributed to a reduction in asthma-related death rates by the 1980s and established inhalers as a standard treatment approach.
The Hall of Fame induction follows selection by a panel of experts across science, engineering, and the patents sector. The inventors will join other recognised figures in medical and scientific innovation, including those associated with insulin and gene editing technologies.
Kindeva said it continues to invest in inhalation drug delivery as part of its contract manufacturing and development activities. The company recently opened a centre of excellence in Loughborough, UK, in September 2025 to support ongoing development in inhalation technologies.
“While we celebrate this landmark achievement, our focus is on the future: delivering next-generation propellants that will improve patient lives, help manufacturers meet global sustainability standards and demonstrate Kindeva’s commitment to ongoing innovation in a dynamic marketplace.”
Jeremy Tidmarsh, Vice President of Kindeva’s MDI business unit
